Pawlyn, C http://orcid.org/0000-0002-7190-0028
Bright, M D
Buros, A F
Stein, C K
Walters, Z
Aronson, L I
Mirabella, F http://orcid.org/0000-0003-3785-6868
Jones, J R
Kaiser, M F
Walker, B A
Jackson, G H
Clarke, P A
Bergsagel, P L http://orcid.org/0000-0003-1523-7388
Workman, P
Chesi, M
Morgan, G J
Davies, F E
Article History
Received: 12 February 2017
Accepted: 23 February 2017
First Online: 31 March 2017
Competing interests
: The Institute of Cancer Research has a commercial interest in the development of epigenetic-modifier inhibitors.